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IMPORTANCE Perioperative chemotherapy and surgery are a standard of care for operable
gastroesophageal adenocarcinoma. Anti-HER2 therapy improves survival in patients with
advanced HER2-positive disease. The safety and feasibility of adding lapatinib to
perioperative chemotherapy should be assessed.
OBJECTIVES To assess the safety of adding lapatinib to epirubicin, cisplatin, and capecitabine
(ECX) chemotherapy and to establish a recommended dose regimen for a phase 3 trial.
DESIGN,SETTING,ANDPARTICIPANTS Phase2randomized,open-labeltrialcomparingstandardECX
(sECX:3preoperativeand3postoperativecyclesofECXwithmodifiedECXplus lapatinib(mECX+L).
Thismulticenter national trialwas conducted in 29 centers in theUnitedKingdom inpatientswith
histologically proven,HER2-positive, operable gastroesophageal adenocarcinoma.Registration
forERBB/HER2 testingtookplacefromFebruary25,2013, toApril 19,2016,andrandomizationtook
placebetweenMay24,2013, andApril 21, 2016.DatawereanalyzedMay 10,2017, toMay25,2017.
INTERVENTIONS Patients were randomized 1:1 open-label to sECX (3 preoperative and 3
postoperative cycles of 50mg/m2 of intravenous epirubicin on day 1, 60mg/m2 intravenous
cisplatin on day 1, 1250mg/m2 of oral capecitabine on days 1 through 21) or mECX+L (ECX plus
lapatinib days 1 through 21 in each cycle and as 6maintenance doses). The first 10 patients in
themECX+L armwere treated with 1000mg/m2 of capecitabine and 1250mg of lapatinib per
day, after which preoperative toxic effects were reviewed according to predefined criteria to
determine doses for subsequent patients.
MAIN OUTCOMES ANDMEASURES Proportion of patients experiencing grade 3 or 4 diarrhea
with mECX+L. A rate of 20% or less was considered acceptable. No formal comparison
between arms was planned.
RESULTS BetweenFebruary 2013, andApril 2016, 441 patients underwent central HER2 testing
and63 (14%)were classified asHER2positive. Forty-six patientswere randomized; 44
(24 sECX, 20mECX+L) are included in this analysis. Twoof the first 10patients in themECX+L
arm reportedpreoperative grade 3diarrhea; thus, nodose increasewasmade. Theprimary
endpoint of preoperative grade 3or 4diarrhea rateswere0of 24 in the sECXarm (0%) and4of
20 in themECX+L arm (21%).Oneof 24 in the sECXarmand3of 20 in themECX+L arm stopped
preoperative treatment early, and for 4 of 19 in themECX+L arm, lapatinib dosewas reduced.
Postoperative complication rateswere similar in each arm.
CONCLUSIONS AND RELEVANCE Administration of 1250mg of lapatinib per day in combination
with ECX chemotherapy was feasible with some increase in toxic effects, which did not
compromise operative management.
TRIAL REGISTRATION ISRCTN.org identifier: 46020948; clinicaltrialsregister.eu identifier:
2006-000811-12
JAMA Oncol. 2019;5(8):1181-1187. doi:10.1001/jamaoncol.2019.1179
Published online June 20, 2019.
Supplemental content
Author Affiliations:Author
affiliations are listed at the end of this
article.
Corresponding Author:David
Cunningham, MD, Royal Marsden
Hospital, London & Sutton, London,
Surrey SM2 5PT, United Kingdom
(david.cunningham@rmh.nhs.uk).
Research
JAMAOncology | Original Investigation
(Reprinted) 1181
Downloaded From: https://jamanetwork.com/ by a University of Bristol User  on 08/12/2019
P erioperative chemotherapyandsurgery improveoverallsurvivalcomparedwithsurgeryaloneinpatientswithop-erable gastroesophageal cancer, and the combination is
a treatment approach recommended by current international
guidelines.1,2 However, because 5-year overall survival for pa-
tients treatedwithcontemporaryperioperative chemotherapy
is less than50%, improvements incurrentlyavailable regimens
areurgentlyneeded.3Overexpressionof thehumanepidermal
growth factor receptor 2 (HER2) protein is found in up to 22%
of gastric and gastroesophageal adenocarcinomas.4 In the
Trastuzumab for Gastric Cancer (ToGA) trial, addition of the
HER2-targetingmonoclonalantibodytrastuzumabtoplatinum-
fluoropyrimidinechemotherapyinadvancedHER2-positivegas-
triccancer improvedradiologic responserates,progression-free
survival,andoverallsurvivalcomparedwithchemotherapy(haz-
ard ratio, 0.74; 95%CI, 0.60-0.91; P = .005).5 The rationale for
the current trialwas to increase thepathologic response rate to
neoadjuvant chemotherapyby theadditionofanti-HER2 treat-
ment,andtherebyto increasecomplete (R0) resectionratesand
overall survival.At the timeof the trialdesign, trastuzumabwas
notprovidedby themanufacturer; therefore, lapatinibwas se-
lected.Wechose lapatinib, adual inhibitorofepidermalgrowth
factorreceptorandHER2availableinanoralpreparation,because
it had shownactivity inpatientswithHER2-positive advanced
gastric cancer treatedwithchemotherapy.6Theprimaryobjec-
tiveof this ST03 lapatinib substudywas toassess the feasibility
andsafetyofcombining lapatinibwithepirubicin,cisplatin,and
capecitabine (ECX) chemotherapy in patients with resectable
esophagogastricadenocarcinoma. If thepilotstudywassuccess-
ful, theaimwas toproceed toa registration trial using the same
combination.ThissubstudywasembeddedwithintheMRCST03
trial,ChemotherapyWithorWithoutBevacizumaborLapatinib
to Treat Operable Oesophagogastric Cancer, the full details of
which are reported elsewhere.7
Methods
Study Design and Participants
This study followed the Consolidated Standards of Reporting
Trials (CONSORT)reportingguideline.Eligibilityforthelapatinib
substudy was considered at 2 time points: before screening to
establish ERBB2/HER2 status, and before randomization of
HER2-positive patients. Registration for ERBB/HER2 testing
took place from February 25, 2013, to April 19, 2016, and
randomization took place betweenMay 24, 2013, and April 21,
2016. Data were analyzed between May 10, 2017, and May 25,
2017.ThestudywaspartoftheST03trialprotocol (Supplement1)
andwasapprovedbyanationalethicscommitteeandtheUnited
Kingdom (UK) Medicines and Healthcare Products Regulatory
Agency(MHRA).Localapprovalwasobtainedatallparticipating
centers. Written informed consent was provided by all
participants before randomization.
Positivity forHER2wasassessedatacentral location (Royal
MarsdenHospital histopathologydepartment) as a score of ≥3
on immunohistochemical staining or a score of ≥2 using the
validated Ventana 4B5 antibody systemwith confirmation of
ERBB2/HER2 gene amplification by dual-color in situ hybrid-
ization and scored according toToGA trial criteria.6 For in situ
hybridization assessments, aHER2:CEP17 ratio of 2 or greater
wasdefinedasamplification.Local testingofERBB2/HER2 sta-
tus was permitted if the local pathology laboratory met pre-
specified criteria (Supplement 1). After HER2 testing at par-
ticipating centers , all cell blockswere recut and restained for
ERBB2/HER2 status confirmation at RoyalMarsdenHospital.
After confirmation of HER2 positivity, full eligibility crite-
ria for the studywereevaluatedbefore randomization.Eligible
patientswereaged18yearsorolderwithadiagnosisoftreatment-
naive, histologically confirmed, lower esophageal, gastric, or
Siewert type1,2,or3esophagogastric junctionadenocarcinoma.
PatientswithgastricandtypeIIIesophagogastric junctiontumors
stagedas Ib (T1N1,T2a/bN0), II, III,orstage IV(T4,N1orN2M0)
byAJCCCancerStagingManual, sixtheditionTNMcriteriawere
eligible.Loweresophagealandtype Ior IIesophagogastric junc-
tion tumors were staged according to theAJCC Cancer Staging
Manual, seventh edition: 0 II*-IVa (*T2N1 not T2N0, T3N0-1,
T4N0-1M0-M1a). Full details canbe found in theTrial Protocol
(Supplement 1).Theonlymajor changemade to theprotocol af-
ter studycommencementwas to includenormalQTdurationas
an inclusion criterion, owing to the effect of lapatinib on QT
interval.
Patientswere randomly assigned in a parallel designusing
1:1 allocation and usingminimization based on chemotherapy
center, tumorsite, tumorstage,andarandomelement (Figure).
The randomizationwasperformedcentrallyusingacomputer-
ized algorithm developed and maintained by the Medical Re-
searchCouncilClinicalTrialsUnit.The randomizationwasper-
formed by research staff calling a central phone line.
Interventions
InthestandardECX(sECX)arm,ECXchemotherapywasadmin-
istered in3preoperativeand3postoperative21-daycycles con-
sistingof50mg/m2epirubicinand60mg/m2cisplatin,both in-
travenous, on day 1 and 1250 mg/m2 oral capecitabine on
days 1 through 21. In the modified ECX (mECX) plus lapatinib
(mECX+L)arm,patientswere treatedwithECXchemotherapy
in 3 preoperative and 3 postoperative 21-day cycles, consisting
Key Points
Question Therapy targeting HER2 increases overall survival in
patients with advanced HER2-positive gastroesophageal cancer
but has not yet been evaluated in patients with potentially curable
disease.
Findings This randomized phase 2 study investigated standard
perioperative chemotherapy with and without lapatinib in patients
with resectable gastroesophageal cancer. Lapatinib at 1250mg/d
in combination with modified epirubicin, cisplatin and
capecitabine chemotherapy (capecitabine dose, 1000mg/mg2/d)
was feasible and did not compromise operative management;
however, toxic effects exceeded predefined acceptable
parameters.
Meaning Biomarker-selected trials in HER2-positive patients with
operable gastroesophageal cancer are feasible, but drug
combinations with lower toxic effects than epirubicin, cisplatin,
and capecitabine plus lapatinib should be evaluated.
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of50mg/m2 intravenousepirubicinand60mg/m2cisplatinon
day 1 and 1000 mg/m2 oral capecitabine on days 1 through 21
plus1250mgof lapatinib takenorallyonday1 through21ofeach
cycle, followedbymaintenancedoseof 1500mgof lapatinib at
taken orally daily for six 21-day cycles.
Postoperative sECX or mECX+L was commenced 6 to 10
weeks after surgery. Patientswere followedup every 6months
after surgery for the first 3 years and every year thereafter until
death, or at comparable timepoints if treatmentwasdiscontin-
uedearly. Chemotherapywasdeliveredby trainedoncologists,
researchnurses,oncologynurses,andsurgeonsatUKhospitals.
Outcomes
Theprimaryobjectiveswere toassess thesafetyofadding lapa-
tinibtoECXchemotherapyandtoestablisharecommendeddose
ofcapecitabineandlapatinibforasubsequentphase3trial.Safety
was chosen as an end point because increasing pathologic re-
sponseratewouldhaverequiredanexcessivenumberofpatients
for thefeasibilitystudy.Secondaryobjectives includeddetermi-
nationof the feasibility of centralizedHER2 testing and confir-
mation of the proportion of HER2-positive cancers in patients
withesophagogastric cancer.Nochanges toassessmentofout-
comes occurred after the feasibility trial commenced.
Figure. CONSORTDiagram
24 Started preoperative chemotherapy
23 3 Cycles (96%)
1 2 Cycles (4%)
7 Did not have surgery
2 Disease progression
4 Inoperable
1 Comorbidity
24 Randomized to sECX
441 Patients screened centrally for HER2
32 Excluded (inoperable or metastatic
cancer, failure to meet eligibility
criteria, timing issues)
31 Met inclusion criteria
63 Positive for HER2
46 Randomized
8 Started postoperative chemotherapy
6 3 Cycles
2 2 Cycles
9 Did not start postoperative chemotherapy
3 Change in condition
1 Unclear
1 Poor histology
2 Intercurrent illness
2 Patient choice
17 Underwent resection
20 Started preoperative chemotherapy
16 3 Cycles (80%)
2 1 Cycle (10%)
2 2 Cycles (10%)
2 Did not start chemotherapy:
omitted from analysis
1 Ineligible
1 Withdrew
3 Did not have surgery
1 Not fit
2 Inoperable
1 Did not start maintenance lapatinib
1 Toxic effects associated with treatment
9 Started maintenance lapatinib
9 Received  6 doses
22 Randomized to mECX + L
10 Started postoperative chemotherapy
9 3 Cycles
1 2 Cycles
7 Did not start postoperative chemotherapy
1 Change in condition
1 Unclear
1 Disease progression
3 Unacceptable toxic effects
1 Patient choice
17 Underwent resection
15 Additional patients positive for HER2
included after local testing
ECX indicates epirubicin, cisplatin,
and capecitabine; mECX+L, modified
ECX plus lapatinib; sECX, standard
ECX.
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Statistical Analysis
The sample size was determined pragmatically, considering
whatwas likely to be feasible andwould provide a reasonable
level of evidence for this initial feasibility assessment. Ran-
domization of 40 patients was expected to require screening
of approximately 400patients,whichwould allow theHER2-
positive rate to be estimated with a reasonable level of accu-
racy. Twenty patients randomized to themECX+L armwould
facilitate an initial safety assessment. Twenty percent or less
of the participants experiencing grade 3 or 4 diarrhea was
deemed tobe acceptable topatients andoncologists and,with
the planned sample size, a 95% CI would exclude a 44% inci-
dence of this adverse event, which was at the upper bound-
ary of acceptability. The sample size was subsequently in-
creased to ensure that 20 patients started treatment in the
mECX+L arm and could contribute to the safety analysis.
To determine a recommended dose of capecitabine plus
lapatinib in themECX+L regimen, formal safety reviewswere
preplanned after 10 and 20 patients completed preoperative
mECX+L. The following dose modification strategy was pre-
specified to be performed after reviewof the first 10 patients:
• If 1 patient or no patients had grade 3 or 4 diarrhea, the dose
ofcapecitabinewouldbe increasedto1250mg/m2for thenext
10 patients.
• If 2 patients had grade 3 or 4 diarrhea, a further 10 patients
would be treated at the samedose level; if nomore than 4 of
20 had grade 3 or 4 diarrhea, this would be the recom-
mended final dose
• If 3 or more patients had grade 3 or 4 diarrhea, the dose of
capecitabine would be maintained at 1000 mg/m2 but the
lapatinib dosewould be reduced to 1000mg/m2 for thenext
10 patients.
The current analysis was performed fromMay 10, 2017, to
May25,2017, approximately 1yearafter the lastpatiententered
the study after all patients had finished trial treatment (allow-
ing a 30-day period after treatment for safety reporting).
Both the interimandfinal analyseswerebasedonstandard
descriptivestatistics,with95%CIswhereappropriate,butnofor-
malhypothesistestingwasperformed.Baselinedataarepresent-
edonan intention-to-treat basis; safety analyses arepresented
by randomized arm but are restricted to those patients who
started treatment in the study. In addition, as detailed in the
Results, therearesomeexclusionsfromtheanalysisowingtothe
availability of data: for example, thosenot undergoing surgery
cannotbe included in theassessmentofpostoperative compli-
cations andpathologic findings. At eachof the formal reviews,
an independent data monitoring committee considered the
totalityofevidence, includingbothdescriptivestatisticsandde-
tailedinformationonadverseeventsbeforemakingarecommen-
dation.No formalhypothesis testingwasperformed.All analy-
seswere carried out in Stata version 14 (StataCorp LLC).
Results
Between February 25, 2013, and April 19, 2016, 441 patients
from 29 UK centers underwent testing at the Royal Marsden
Hospital for ERBB/HER2 status (eFigure 1 in Supplement 2).
The median (range) time between registration for HER2 test-
ing and result reporting was 6 (1-31) days. The proportion of
HER2-positive esophagogastric cancers basedon central test-
ing was 63 of 441 (14.3%; 95% CI, 11.2%-17.9%). This propor-
tion does not include patients tested for HER2 at local cen-
ters, because these patients were only registered when
identified as HER2-positive by the central laboratory. Of the
63 centrally tested HER2-positive patients, 31 were random-
ized. Reasons for HER2-positive patients not being random-
ized included inoperable ormetastatic cancer, failure tomeet
full eligibility criteria, and timing of investigations or treat-
ment. A further 15 patientswere randomized after HER2 test-
ing at 7 local centers; among these patients, 8 (53%) cancers
were confirmed as HER2 positive after central testing.
Forty-six patients were enrolled; 24 were randomly as-
signed to receive sECX, and 22 were randomized to receive
mECX+L. Baseline characteristics were similar between the 2
groups (Table). Median (IQR) age was 64 (56-69) years, 35 of
46 (76%) patientsweremale and 36 of the 46 (78%) had clini-
cal stage III disease or greater at study entry.
The planned safety review, after 10 patients had com-
pleted preoperative treatment in the mECX+L arm, was per-
formed inNovember 2014.Nodosemodificationsweremade
asa resultof this review(furtherdetailsbelow).The final safety
analysis, reported herein, once all patients had finished trial
treatment and allowing a 30-day period after treatment for
safety reporting.
Preoperative dose delays occurred in 12 of 71 (17%) sECX
cycles involving 10 of 24 (42%) patients and in 8 of 54 (15%)
mECX+L cycles involving 7 of 20 (35%) patients. Preoperative
dose reductionsoccurred in 11of 71 (15%)sECXcycles involving
9 of 24 (38%) patients and in 12 of 54 (22%)mECX+L cycles in-
volving9of20(45%)patients.The leadingcauseofcycledelays
anddosereductionswastoxiceffects(toxiceffectsdetailsarepro-
vided in eTable 1 in Supplement 2). Four patients treated with
preoperative mECX+L had their lapatinib dose reduced from
1250mg/d to 1000mg/d,with 1patienthavinga further reduc-
tion to750mg/d.All dose reductionswerebecauseofdiarrhea.
Thesedatawerenotavailablefor1patientreceivingmECX+L
whowithdrewonday 1 of cycle 1 andwas, therefore, excluded
fromthis analysis. Themost commonpreoperative toxic effect
inbothstudyarmswasneutropenia,occurringin10of19patients
(53%) inthemECX+Larmand13of24patients (54%) inthesECX
arm; febrile neutropenia occurred in 1 patient treated with
mECX+L.Grade3or4diarrheaoccurred in4of 19 (21%;95%CI,
6%-46%) patients treatedwithmECX+L but in none of the pa-
tients treatedwithsECX.Toxiceffectsmorecommoninpatients
treatedwithpreoperativemECX+Lweregrade 1or2 stomatitis,
which occurred in 11 of 19 (58%) in themECX+L arm vs 7 of 24
(29%) in the sECX arm, and vomiting of any grade, which oc-
curred in 11 of 19 (58%) in themECX+L arm vs 7 of 24 (29%) in
the sECX arm.No patient died as a result of study treatment.
Ancillary analyses, which would not inform a definitive
trial, includedpathologic assessment andpostoperative treat-
ment tolerability. Pathology data were available for 16 pa-
tients in the sECXarmand 17patients in themECX+Larm. Lo-
cal pathologic assessment of resection specimens showed a
complete resection (R0) for 11 of 16 (69%)patients treatedwith
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sECXand12of 17 (71%)patients treatedwithmECX+L (eTable2
in Supplement 2). At least 15 lymph nodes were evaluated by
a pathologist in 14 of 16 (88%) patients treatedwith sECX and
14 of 17 (82%) patients treated with mECX+L.
Onepatient treatedwith sECX (6%)was found tohavedis-
tantmetastases at resection; this was not the case for any pa-
tient treated with mECX+L. Of 23 patients for whom a Man-
dard tumor regression gradewas reported, 1 patient of 11 (9%)
treated with sECX had a tumor regression grade of 1 to 2; this
was true of 3 of 12 (25%) patients treated with mECX+L.
Postoperative data are available for all 34 patients (17 in
each arm) who underwent surgical resection (eTable 3 in
Supplement 2). Eight of the 17 (47%) of patients in the sECX
armand 10 of the 17 (59%) in themECX+L armexperienced at
least 1 complication. The incidence of anastomotic leak was
similar in patients treated with mECX+L (2 of 17 [12%]) and
sECX (3 of 17 [18%]). Two of 17 patients in the mECX+L arm
(12%), required revision surgery (1 for ischemic bowel, 1 for
chyle leak); no patient in the sECX arm had a second opera-
tive procedure.
Postoperative chemotherapy commencedafter 8weeksor
later after surgery in 8 of 17 (47%) patients receiving sECX and
10of 17 (59%) receivingmECX+L.Postoperative chemotherapy
wasdelayed inat least 1 cycle for 5of8 (63%)patients receiving
sECXand6of10(60%)receivingmECX+L.Fiveof8 (63%)ofpa-
tients in the sECX arm and 7 of 10 (70%) themECX+L arm had
at least 1 chemotherapydose reductionpostoperatively.Fiveof
the10patients inthemECX+Larm(50%)hadtheir lapatinibdose
reduced during the postoperative phase.
The rate of toxic effects in the postoperative setting was
similar to that recorded preoperatively (eTable 2 in Supple-
ment 2). None of the patients had a clinically relevant drop in
ejection fraction while receiving study treatment.
Five cases of grade 3 diarrhea occurred in patients treated
withmECX+L.Fourof thesecasesoccurredpreoperativelyand
werepotentially related to treatment (4of 19 [21%];95%CI,6%-
46%).Onepatient hadgrade 3diarrheapostoperatively,which
wasdeemedunrelatedtotreatment.Atthefirstplanneddosees-
calation review (based on the first 10 patients completing pre-
operativemECX+L),all feasibilitydataforthetrialwerereviewed
by the independentdatamonitoringcommittee, and, although
3of10patients(30%;95%CI,7%-65%)hadexperienceddiarrhea
events, the events in 2 patients were felt to be related to treat-
ment. Because rates of other toxic effects such as neutropenia
were also higher in themECX+L arm, a decisionwasmade not
toescalatethedoseofcapecitabineatthatpoint.Therefore,based
on the prespecified dose escalation strategy, no escalation of
mECX+Ldoseto1250mg/m2ofcapecitabinewasrecommended
duringthestudy.Theresultspresentedhereinconcludethesec-
ond planned safety review.
Twelve patients treated in the study (6 per arm) died. All
deaths were disease related.
Table. Baseline Patient Characteristics
Characteristic
No. (%)
sECX mECX+L Total
Male sex 21 (88) 14 (64) 35 (76)
Age, median (IQR) [range], y 65 (57-68) [45-78] 63 (54-71) [38-74] 64 (56-69) [38-78]
WHO performance status
Normal activity 17 (71) 14 (64) 31 (67)
Restricted in physical activity 7 (29) 8 (36) 15 (33)
Site of tumor
Lower esophageal 8 (33) 7 (32) 15 (33)
EGJ (type I) 4 (17) 5 (23) 9 (20)
EGJ (type II) 4 (17) 4 (18) 8 (17)
EGJ (type III) 4 (17) 2 (9) 6 (13)
Stomach 4 (17) 4 (18) 8 (17)
Pretreatment Tumor Staging TNM6
Gastric and type III EGJ
No. 8 6 14
T3 N0 M0 (stage II) 0 (0) 1 (17) 1 (7)
T3 N1 M0 (stage IIIa) 1 (13) 4 (67) 5 (36)
T3 N2 M0 (stage IIIb) 3 (38) 1 (17) 4 (29)
T4 N1-N2 M0 (stage IV) 4 (50) 0 (0) 4 (29)
Lower esophageal/type I or II EGJ
No. 16 16 32
T3 N0 M0 (stage IIa) 0 (0) 4 (25) 4 (13)
T1 N1 M0 (stage IIb) 1 (6) 0 (0) 1 (3)
T2 N1 M0 (stage IIb) 4 (25) 0 (0) 4 (13)
T3 N1 M0 (stage III) 10 (63) 12 (75) 22 (69)
T4 N0-N1 M0 (stage III) 1 (6) 0 (0) 1 (3)
Total, No. 24 22 46
Abbreviations: ECX, epirubicin,
cisplatin, and capecitabine;
mECX+L, modified ECX plus lapatinib;
EGJ, esophagogastric junction;
sECX, standard ECX; WHO,World
Health Organization.
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Discussion
In this analysis, we present the results of a randomized feasi-
bility study of standard perioperative ECX chemotherapy vs
dose-modified ECX plus lapatinib in patients with operable
HER2-positive gastroesophageal adenocarcinoma. This is, to
thebestofourknowledge, the first reportonacompletedphase
II randomized trial of HER2-directed therapy in operable gas-
troesophageal cancer. We initiated a screening program for
ERBB/HER2 status in gastroesophageal cancer at 29 UK cen-
tersandcentrally screened441patientsandconfirmedaHER2-
positive rate of 14% in this UK cohort. Forty-six patients were
treated in the study.We found that, evenwith amodification
of the capecitabinedose, the additionof lapatinib tomECXre-
sulted in clinically significant diarrhea in 5 of 22 (21%) of pa-
tients treated, which was higher than the rate we considered
acceptable for patient safety. For this reason, it is suggested
that any future trials combining these compounds shouldnot
escalate the capecitabine dose beyond 1000mg/m2/d.
Theprimaryaimof thisstudywastoestablishasafeandtol-
erable regimenfor lapatinibcombinedwithECXchemotherapy
in patients with gastroesophageal cancer to inform the design
of futurestudies. Inaddition to thegastrointestinal toxiceffects
observedinourtrialandlackofobservedincreaseinefficacywith
respect topathologic response rates, the recent results fromthe
Fluorouracil plus leucovorin, oxaliplatinanddocetaxel4Arbe-
itsgemeinschaft Internistische Onkologie (FLOT4 AIO) trial3,7
demonstratingbetteroutcomeswithFLOT(fluorouracil, oxali-
platin, leucovorin, and docetaxel chemotherapy compared
with previous trials with ECX, and the negative results of the
TRIO-013(TranslationalResearchinOncology)/LOGiC(Lapatinib
Optimization Study in the HER2-Positive Gastric Cancer) trial,
inwhich lapatinibwas combinedwith capecitabine and oxali-
platin,andtheLapatinib[Tykerb]withPaclitaxel [Taxol] inAsian
ErbB2+[HER2+] Gastric Cancer Study, (TyTAN ) trial, in which
lapatinibwascombinedwithpaclitaxel inthemetastaticsetting,
mean that it isunlikely tobe feasible todevelopa lapatinibplus
ECX combination in this patient group.8,9
Thesecondaryobjectivesof this trialwere toassess the fea-
sibilityofcentralbiomarkerassessment foranational trial in the
perioperative setting. We observed 14.3% of patients to have
HER2-positivecancersaccording tostudycriteria,which iscon-
sistentwithother series andmay informfuture trial design.10,11
Central testingofERBB/HER2statuswasfelt tobenecessaryow-
ingtothespecial laboratoryrequirementsforHER2testingingas-
troesophagealcancer,whichwerenotavailable inmanyUKcen-
tersat thetimeofstudydesign.Themedianturnaroundtimefor
centrallytestedHER2resultswas6days,whichdidnotintroduce
any undue delay into the treatment pathway andwas satisfac-
toryforpatientsandinvestigators.Duringthecourseofthestudy,
severalmajor centers achievednationally recognizedcertifica-
tionforHER2testingandwerethereforegivenpermissiontoper-
form localHER2 testing. Although local testing for study entry
canincreaserecruitment,centralconfirmationofbiomarkersta-
tus is likely to be required for any registration trial. This is par-
ticularly important inviewof theheterogeneityofERBB/HER2
statusobserved ingastroesophageal cancer, andhighlightedby
thediscrepanciesbetweenlocalandcentral testingresults inour
data set.4Half of patientswhohadHER2-positive tumorswere
notrandomized,predominantlyowingto ineligibility.Topermit
screening of the largest proportion of patientswithin the short
perioperative time frame, a permissive approach toprescreen-
ingeligibilitywasused, followedbyfulleligibilityassessmentaf-
terHER2positivityhadbeenestablished.Higher ratesof screen
failuremight be expectedwhen following such an approach.
Neitherthefeasibilityofsurgerynorsurgicalmorbiditywere
compromised by the addition of lapatinib to mECX chemo-
therapy.Aprevious trialusing lapatinib inconjunctionwithca-
pecitabineandoxaliplatinchemotherapywashaltedbecauseof
anastomotic leaks in2patients;no increase inanastomotic leaks
wasobservedinlapatinib-treatedpatients inourstudy.12Therate
of R0 resectionwas comparable in both arms of this study and
consistent with that demonstrated in the phase 3 randomized
ST03ECXplusorminusbevacizumabcomparison.13After local
pathologic review, complete tumor regression rates (25%)were
encouraginginpatientswhoreceivedmECX+L;however, thisas-
sessment is based on 23 patients.
Limitations
Onelimitationofthecurrentstudyisitsrelativelysmallsize.How-
ever, in the context of a national biomarker selected trial per-
formedintheperioperativesetting,which issubject totimecon-
straints, recruitmentappearsmore impressive.Theuseofwhat
is now considered a less-optimal chemotherapy regimen and
HER2-targetedtreatmentinthispatientgroupmaybepotentially
subject tocriticism.At thetimeof trialdesign,ECXwasarecom-
mended standard of care; and recruitmentwas completed be-
foreemergingdataabout theFLOTregimen.AdoptionofFLOT
as thenewperioperative standard offers an excellent opportu-
nitytocombineHER2-directedtherapywitharegimenthatcon-
tainsnopotentially cardiotoxic agents, unlikeECX.This is cur-
rentlybeinginvestigatedintheongoingNeoadjuvantStudyUsing
TrastuzumaborTrastuzumabWithPertuzumabinGastricorGas-
troesophagealJunctionAdenocarcinoma(EORTCINNOVATION)
and FLOT vs FLOT/Herceptin/Pertuzumab for Perioperative
Therapy of HER-2 Expressing Gastric or GEJ Cancer (AIO
PETRARCA)perioperativestudies.Thesetrialsareimportant,be-
causealthoughtheadditionofpertuzumabtotrastuzumabplus
chemotherapydidnot improveoverallsurvival intheJACOBtrial
(AStudyofPertuzumab inCombinationWithTrastuzumaband
Chemotherapy inParticipantsWithHumanEpidermalGrowth
FactorReceptor2 [HER2]-PositiveMetastaticGastroesophageal
Junction or Gastric Cancer in HER2-Positive Advanced Gastric
Cancer), an improvement in radiologic response rates was
observed.14 Other limitations include potential bias in patient
selection, remaining uncertainty surrounding feasibility, and,
potentially,multiplicity.
Conclusions
Althoughtheexternalvalidityof thestudymaybelimitedbythe
useof lapatinibwhenmoreeffectiveHER2-targetingdrugshave
nowbeen developed, the trial design and structureswere suc-
cessful andcouldbeused in the future forother similar trials in
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this setting.Tocapitalizeon theworkconducted in the current
study,atranslationalprotocol,whichwill includegenomic, tran-
scriptomic, andproteomic analysis ofHER2-associated signal-
ingpathways is planned. It is hoped that the results of this pro-
gramwill help to elucidate further opportunities for targeting
HER2 in this challenging heterogenous disease.
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